Lauren Santye, Assistant Editor

High-risk soft tissue sarcoma patients given anthracycline plus ifosfamide were found to have significant increases in survival.

Pseudomonas aeruginosa causes infections in patients with HIV, cancer, and other immune-compromised disease states.

Top news of the day from across the health care landscape.

Superior progression-free survival achieved with cabozantinib over sunitinib in patients with metastatic renal cell carcinoma.

Supplements given to prostate cancer patients following radiotherapy could harm disease outcomes.

A component found in red wine and grapes may help manage inflammation caused by a bacterial pathogen associated with upper respiratory tract inflammatory diseases.

Immunotherapy showed promise in first- and second-line therapy for patients with metastatic bladder cancer.

Survey findings show a high level of integration of palliative care in advanced cancer patients.

Top news of the day from across the health care landscape.

A treatment for multiple sclerosis that treats the most common form of the disease may help reverse some physical disabilities.

Mark A. Vineis, vice president of Specialty Pharmacy at Cardinal Health, discusses how the growing population of older Americans could impact the specialty pharmacy landscape.

Researchers created a technique that targets HIV reservoirs.

Top news of the day from across the health care landscape.

Entyvio treats moderate-to-severe active ulcerative colitis and Crohn’s disease.

New data indicates men of African American and Hispanic descent are less likely to undergo therapy for prostate cancer compared with Caucasian men.

A small proportion of HIV-infected children do not develop AIDS by controlling the virus in a different way than infected adults who remain disease-free.

Entyvio is a humanized monoclonal antibody for patients with moderate-to-severe ulcerative colitis and Crohn’s disease.

Targeting the uracil-DNA glycosylase enzyme may help treat certain types of non-Hodgkin’s lymphoma.

Top news of the day from across the health care landscape.

Recent findings suggest the implementation of intervention programs that target young males of a lower socio-economic status, non-cancer and cancer survivors, and cervical cancer survivors to help reduce the consumption of sugary drinks and added sugar.

FDA approves Lartruvo based on overall survival improvements in patients with soft tissue sarcoma.

Treating financial toxicity in cancer patients similarly to other side effects could improve outcomes.

Lartruvo with doxorubicin significantly improves overall survival in patients with soft tissue sarcoma.

Patients with Crohn’s disease achieve highest clinical response and remission rates during an early study.

Relapsed metastatic head-and-neck cancer patients who received nivolumab experienced a reduction in symptoms.

Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses lessons the specialty industry learned from the impact of high cost drug launches for hepatitis C and high cholesterol.

Top news of the day from across the health care landscape.

An update of distribution and circulation of HCV genotypes could help reduce disease burden.

Compared with standard-of-care for patients with inflammatory bowel disease (IBD), a new study found that medication therapy management (MTM) increased adherence more than 30%.

Tecentriq is the first anti-PDL1 cancer immunotherapy approved for metastatic non-small cell lung cancer.